BR005-036C not checked
Brise Pharmaceuticals Co., Ltd.
FollowEvery change as it happens, and a Monday email
Trials
2 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Migraine, With or Without Aura (2 trials)
- Main trialPhase 3
- “The purpose of this study is to evaluate the long-term safety of BR005-036C tablets in the acute treatment of migraines”In the company’s words, NCT07835152 on ClinicalTrials.gov
Other drugs for Migraine, With or Without Aura
- ElismetrepTriGemX Bio, Inc. · Tanabe Pharma Corporation · Phase 3
- UbrogepantAbbVie · Phase 3
- EptinezumabH. Lundbeck A/S · Phase 3
- AtogepantAbbVie · Phase 3
- ErenumabAmgen · Phase 3
- MEDI0618AbbVie · Phase 2
Coming up2
- 30 Jun 2028Phase 2/3 trial completes · ClinicalTrials.gov
- 31 Mar 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | 31 Mar 2029 | Long-term Safety of BR005-036C Tablets in the Acute Treatment of Migraine in Adults | |
| Phase 2/3Recruiting | 30 Jun 2028 | Efficacy and Safety of BR005-036C Tablets for the Acute Treatment of Migraine in Adults |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026